Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.

Saved in:
Bibliographic Details
Title: Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.
Authors: Craft CS; Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, Northwestern University and the Robert H Lurie Cancer Center of Northwestern University, Chicago, IL, USA., Romero D, Vary CP, Bergan RC
Source: Oncogene [Oncogene] 2007 Nov 08; Vol. 26 (51), pp. 7240-50. Date of Electronic Publication: 2007 May 14.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0950-9232 (Print) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:0950-9232
DOI:10.1038/sj.onc.1210533